Former England Soccer Coach Sven-Goran Eriksson Says He ‘Maybe’ Has A Year Left To Live
“At best I have maybe a year, at worst maybe a little less,” said England’s first-ever foreign-born soccer coach.
“At best I have maybe a year, at worst maybe a little less,” said England’s first-ever foreign-born soccer coach.
An employee works on the production line of pharmaceutical company Zentiva in Prague, Czech Republic, May 6, 2021. David W. Cerny | Reuters The health-care sector has wiped out much of its losses for the year during the December market rally. Beaten-down biotech and medical device makers have seen the biggest rebound this month, and…
With multiple respiratory viruses swirling this time of year, it can be hard to know which sickness you’re dealing with. But with cases of flu on the rise in much of the country, it’s important to know the signs of this virus — and doctors say there are some telltale signs. “Symptoms of the flu…
A recent study by the University of Exeter and Maastricht University published in JAMA Neurology has identified some of the factors that can lead to early cases of dementia ― some of which may surprise you. The data analyzed the behaviors of over 350,000 participants younger than 65 across the United Kingdom to evaluate young-onset…
DealsGovernmentHealth 06 November 2023, 6:28 pm 1 minute Reuters was first to report that U.S. health insurer Cigna Group (CI.N) is exploring the sale of its Medicare Advantage business, which manages government health insurance for people aged 65 and older, a move that would mark a reversal of its expansion in the sector. Market Impact…
When it comes to setting healthy resolutions for the New Year, sleep is just as essential as nutrition and exercise, experts agree. A lack of sleep can put you at a greater risk for obesity, high blood pressure, type 2 diabetes, heart disease, poor mental health and even early death, according to the Centers for…
An entry sign to the Johnson & Johnson campus shows their logo in Irvine, California on August 28, 2019. Mark Ralston | AFP | Getty Images Johnson & Johnson on Monday said it will pay $2 billion in cash to acquire Ambrx Biopharma, a drugmaker specializing in one of the hottest areas of cancer treatment….